The new bone biology: Pathologic, molecular, and clinical correlates

American Journal of Medical Genetics, Part A

Volumn 140, Issue 23, 2006, Pages 2646-2706

  Cohen Jr , M Michael ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

ACVR1; BMPs; Bone tumors; Cartilaginous tumors; Collagenopathies; Endochondral bone; FGFRs; IHH; Leptin; Membrane bone; MSXs; Osteoclastogenesis; Osteoimmunology; Osteopetrosis; Osteoporosis; PTH; PTHR1; RANK; RANKL; RUNX2; Skeletal dysplasias; TGF s; WNT signaling

Indexed keywords

ADENYLATE CYCLASE; BETA CATENIN; COLLAGEN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GUANINE NUCLEOTIDE BINDING PROTEIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE 4; LEPTIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TRANSCRIPTION FACTOR OTX; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN;

ACVR1 GENE; ALBERS SCHOENBERG DISEASE; ALBRIGHT SYNDROME; ANKH GENE; BONE DEVELOPMENT; BONE DISEASE; BONE DYSPLASIA; BONE REMODELING; BONE STRUCTURE; CHONDROCALCINOSIS; CHONDRODYSPLASIA; CHONDROGENESIS; CLEIDOCRANIAL DYSPLASIA; CONFERENCE PAPER; CRANIOFACIAL SYNOSTOSIS; DISEASE ASSOCIATION; ENCHONDRAL OSSIFICATION; ENZYME ACTIVATION; FIBROUS DYSPLASIA; FLNA GENE; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC DISORDER; GNAS1 GENE; GROWTH PLATE; HISTOPATHOLOGY; HUMAN; HYPEROSTOSIS; IHH GENE; LRP5 GENE; MARFAN SYNDROME; MOLECULAR BIOLOGY; MSX1 GENE; MSX2 GENE; NONHUMAN; OSSIFYING MYOSITIS; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PTHR1 GENE; RECEPTOR GENE; RUNX2 GENE; SIGNAL TRANSDUCTION; TOOTH DEVELOPMENT;

ANIMALS; BONE DEVELOPMENT; BONE DISEASES; BONE MORPHOGENETIC PROTEINS; BONE REMODELING; CARTILAGE; HUMANS; MODELS, BIOLOGICAL; MUTATION; OSTEOBLASTS; OSTEOCLASTS; SIGNAL TRANSDUCTION;

EID: 33644872519     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.31368     Document Type: Conference Paper

References (431)

1. ADHR Consortium. 2000. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGFR3. Nat Genet 26:345-348.
2. Ai M, Holmen SL, Van Hul W, Williams BO, Warman ML. 2005a. Reduced affinity to and inhibition by DKK1 from a common mechanism by which high bone mass-associated missense mutations in LRP5affect canonical Wnt signaling. Mol Cell Biol 23:4946-4955.
3. Ai M, Heeger S, Bartels CF, Schelling DK, The Osteoporosis-Pseudoglioma Collaborative Group. 2005b. Clinical and molecular findings in osteoporosis-pseudoglioma syndrome. Am J Hum Genet 77:741-753.
4. Albers-Schönberg H. 1904. Röntgenbilder einer seltenen Knochenerkrankung. Muenchener Med Wschr 51:365.
5. Alliston T, Derynck R. 2002. Interfering with bone remodeling. Nature 416:686-687.
6. Alman BA, Greel DA. 1996. Activating mutations of Gs protein in monostotic fibrous lesions of bone. J Orthop Res 14:311-315.
7. Angier N. 1994. New York Times. Nov. 1.
8. Annes JP, Munger JS, Rifkin DB. 2003. Making sense of latent TGFβ activation. J Cell Sci 116:217-224.
9. Arron JR, Choi Y. 2000. Bone versus immune system. Nature 408:535-536.
10. Ayad S, Boot-Hanford RP, Humphries MJ, Kadler KE, Shuttleworth CA. 1994. The extracellular matrix. New York, Academic Press.
11. Baldock PA, Sainsbury A, Couzens M, Enriquez RF, Thomas GP. 2002. Hypothalamic Y2 receptors regulate bone formation. J Clin Invest 109:915-921.
12. Banerjee C, McCabe LR, Choi J-Y, Hiebert SW, Stein JL, Stein GS, Lian JB. 1997. Runt homology domain proteins in osteoblast differentiation: AML-3/Cbfa1 is a major component of a bone specific complex. J Cell Biochem 66:1-8.
13. +-ATPase β-subunit. Gene 160:157-164.
14. Bartsch O, Wuyts W, Van Hul W, Hecht JT, Meinecke P, Hogue D, Werner W, Zabel B, Kinkel GK, Powell CM, Shaffer LG, Willems PJ. 1996. Delineation of a contiguous gene syndrome with multiple exostoses, enlarged parietal foramina, craniofacial dysostosis, and mental retardation, caused by deletions on the short arm of chromosome 11. Am J Hum Genet 58:734-742.
15. Bastepe M, Fröhlich LF, Hendy GN, Indridason OS, Josse RG, Koshiyama RGH, Körkkö J, Nakamoto JM, Rosenbloom AL, Slyper A, Sugimoto T, Tsatsoulis A, Crawford JD, Jüppner H. 2003. Autosomal dominant pseudohypoparathyroidism type Ib is associated with a microdeletion that likely disrupts a putative imprinting control element of GNAS. J Clin Invest 112:1255-1263.
16. Bastepe M, Fröhlich LF, Linglart A, Abu-Zahra HS, Tojo K, Ward LM, Jüppner H. 2004. Deletion of the NESP55 differentially methylated region causes loss of maternal GNAS imprints and pseudohypoparathyroidism type Ib. Nat Genet 37:25-27.
17. Bates SH, Kulkarni RN, Seifert M, Myers MG Jr. 2005. Roles for leptin receptor/STAT3-dependent and -independent signals in the regulation of glucose homeostasis. Cell Metab 1:169-178.
18. Bell JR, Noveen A, Liu Y-H, Ma L, Dobias S, Kundu R, Juo W, Xia Y, Lusis AJ, Snead ML, Maxson R. 1993. Genomic structure, chromosomal location, and evolution of the mouse. Hox 8 gene. Genomics 16:123-131.
19. Bell DM, Leung KKH, Wheatley SC, Ng LJ, Zhou S, Ling KW, Sham MH, Koopman P, Tam PPL, Cheah KSE. 1997. SOX9 directly regulates the type-II collagen gene. Nat Genet 16:174-178.
20. Bellaiche Y, The I, Perrimon N. 1998. Tout-velu is Drosophila homologue of the putative tumour suppressor EXT-1 and is needed for Hh diffusion. Nature 394:85-88.
21. Bellus GA, Hefferon TW, Ortiz DE, Luna RI, Hecht JT, Horton WA, Machado M, Kaitila I, McIntosh I, Francomano CA. 1995a. Achondroplasia is defined by recurrent G380R mutations of FGFR3. Am J Hum Genet 56:368.
22. Bellus GA, McIntosh I, Smith EA, Aylsworth AS, Kaitila I, Horton WA, Greenaw GA, Hecht JT, Francomano CA. 1995b. A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia. Nat Genet 10:357-359.
23. Bellus GA, Gaudenz K, Zackai EH, Clarke LA, Szabo J, Francomano CA, Muenke M. 1996. Identical mutations in three different fibroblast growth factor receptor genes in autosomal dominant craniosynostosis syndromes. Nat Genet 14:174-176.
24. Bellus GA, Bamshed MJ, Przylepa KA, Dorst J, Lee RR, Hurko O, Jabs EW, Curry CJR, Wilcox WR, Lachman RS. 1999. Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): Phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3. Am J Med Genet 85:53-65.
25. Bellus GA, Spector EB, Speiser PW, Weaver CA, Garber AT, Bryke CR, Israel J, Rosengren SS, Webster MK, Donoghue DJ, Francomano CA. 2000. Distinct missense mutations of the FGFR3 Lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype. Am J Hum Genet 67:1411-1421.
26. Benson MD, Aubin JE, Xiao ZS, Thomas PE, Francesche RT. 1999. Cloning of 2.5 kb murine bone sialoprotein promotor fragment and functional analysis of putative Osf2 binding sites. J Bone Miner Res 14:396-405.
27. Beresford WA. 1981. Chondroid Bone, Secondary Cartilage and Metaplasia. Baltimore-Munich: Urban and Schwarzenberg.
28. Berger E. 2005. Findings may prevent osteoporosis. Houghton Chemical, March 10.
29. Bi W, Huang W, Deng JM, Zhang Z, Behringer RR, de Crombrugghe B. 1999. Sox9 is required for cartilage formation. Nat Genet 22:85-89.
30. Bi W, Huang W, Whitworth DJ, Deng JM, Zhang Z, Behringer RR, de Crombrugghe B. 2001. Haploinsufficiency of Sox9 results in defective cartilage primordial and premature skeletal mineralization. Proc Nat Acad Sci 98:6698-6703.
31. Blair HC. 1998. How the osteoclast degrades bone. BioEssays 20:837-846.
32. Blair HC, Teitelbaum SL, Ghisell R, Gluck S. 1989. Osteoclastic bone resorption by a polarized vacuolar proton pump. Science 245:855-857.
33. Blomstrand S, Claesson I, Save-Soderbergh J. 1985. A case of lethal congenital dwarfism with accelerated skeletal maturation. Pediat Radiol 15:141-143.
34. Boileau C, Jondeau G, Mizuguchi T, Matsumoto N. 2005. Molecular genetics of Marfan syndrome. Curr Opin Cardiol 20:194-200.
35. Bonaventure J, Rousseau F, Legeai-Mallet L, Le Merrer M, Munnich A, Maroteaux P. 1996. Common mutations in the fibroblast growth factor receptor 3 (FGFR3) gene account for achondroplasia, hypochondroplasia and thanatophoric dwarfism. Am J Med Genet 63:148-154.
36. Bonewald LF. 1996. Transforming growth factor-β. In: Bilezikian J, Raisz L, Rodan G, editors. Principles of Bone Biology. New York: Academic Press, p. 647-659.
37. Borysenko M, Beringer T. 1984. Functional Histology. Second Edition. Boston: Little, Brown & Company.
38. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP. 2002. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346:1513-1520.
39. Boyle WJ, Simonett WS, Lacey DL. 2003. Osteoclast differentiation and activation. Nature 423:337-342.
40. Brodie SG, Kitoh H, Lachman RS, Nolasco LM, Mekikian PB, Wilcox WR. 1999. Platyspondylic lethal skeletal dysplasia, San Diego type, is caused by FGFR3 mutations. Am J Med Genet 84:476-480.
41. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS. 1998. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260-1268.
42. Burke D, Wilkes D, Blundell TL, Malcolm S. 1998. Fibroblast growth factor receptors: Lessons from the genes. Trends Biochem 23:59-62.
43. Byers PH, Steiner RD. 1992. Osteogenesis imperfecta. Annu Rev Med 43:269-282.
44. Bénichou O, Cleiren E, Gram J, Bollerslev J, de Vernejoul M-C, Van Hul W. 2001. Mapping of autosomal dominant osteopetrosis type II (Albers-Schönberg disease) to chromosome 16p13.3. Am J Hum Genet 69:647-654.
45. Camera G, Baldi M, Strisciuglio G, Concolino D, Mastroiacovo P, Baffico M. 2001. Occurrence of thanatophoric dysplasia type I (R248C) and hypochondroplasia (N540K) mutations in two patients with achondroplasia phenotype. Am J Med Genet 104:277-281.
46. Candeliere GA, Glorieux FH, Prud'homme J, St-Arnaud R. 1995. Increased expression of the c-fos proto-oncogene in bone from patients with fibrous dysplasia. N Engl J Med 332:1546-1551.
47. Candeliere GA, Roughley PJ, Glorieux FH. 1997. Polymerase chain reaction-based technique for the selective enrichment and analysis of mosaic arg201 mutations in G alpha s from patients with fibrous dysplasia of bone. Bone 21:201-206.
48. Carpenter TO. 2003. Oncogenic osteomalacia - a complex dance of factors. N Engl J Med 348:1705-1708.
49. Catron KM, Wang H, Hu G, Shen MM, Abate-Shen C. 1996. Comparison of MSX-1 and MSX-2 suggests a molecular basis for functional redundancy. Mech Dev 55:185-199.
50. Centrella M, Horowitz MC, Wozney JM, McCarthy TL. 1994. Transforming growth factor-β gene family members and bone. Endocrinol Rev 15:27-39.
51. Chaki S, Kawashima N, Suzuki Y, Shimazaki T Okuyama S. 2003. Cocaine- and amphetamine-regulated transcript peptide produces anxiety-like behavior in rodents. Eur J Pharmacol 464:49-54.
52. Choi J-Y, Pratap J, Javed A, Zaidi SK, Xing L, Balint E, Dalamangas S, Boyce B, van Wijnen AJ, Lian JB, Stein JL, Jones SN, Stein GS. 2001. Subnuclear targeting of Runx/Cbfa/AML factors is essential for tissue-specific differentiation during embryonic development. Proc Natl Acad Sci USA 97:10549-10554.
53. Chrzanowska K, Kozlowski K, Kowalska A. 1998. Syndromic foramina parietalia permagna. Am J Med Genet 78:401-405.
54. Cohen MM Jr. 1997a. Short limb skeletal dysplasias and craniosynostoses: What do they have in common? Pediatr Radiol 27:442-446.
55. Cohen MM Jr. 1997b. Transforming growth factor βs and fibroblast growth factors and their receptors. Role in sutural biology and craniosynostosis. J Bone Miner Res 12:322-331.
56. Cohen MM Jr. 1998. Achondroplasia, hypochondroplasia, and thanatophoric dysplasia: Clinically related skeletal dysplasias that are also related at the molecular level. Int J Oral Maxfac Surg 27:451-455.
57. Cohen MM Jr. 2000a. Merging the old skeletal biology with the new. I. Intramembranous ossification, endochondral ossification, ectopic bone, secondary cartilage, and pathologic considerations. Craniofac Genet Dev Biol 20:84-93.
58. Cohen MM Jr. 2000b. Merging the old skeletal biology with the new. II. Molecular aspects of bone formation and bone growth. J Craniofac Genet Dev Biol 20:94-106.
59. Cohen MM Jr. 2000c. Craniofacial disorders caused by mutations in homeobox genes MSX1 and MSX2. J Craniofac Genet Dev Biol 20:19-25.
60. Cohen MM Jr. 2001a. RUNX genes, neoplasia, and cleidocranial dysplasia. Am J Med Genet 104:185-188.
61. Cohen MM Jr. 2001b. Fibrous dysplasia is a neoplasm. Am J Med Genet 98:290-293.
62. Cohen MM Jr. 2002a. Some chondrodysplasias with short limbs: Molecular perspectives. Am J Med Genet 112:304-313.
63. Cohen MM Jr. 2002b. Bone morphogenetic proteins with some comments on fibrodysplasia ossificans progressiva and NOGGIN. Am J Med Genet 109:87-92.
64. Cohen MM Jr. 2003a. TGFβ/Smad signaling system and its pathologic correlates. Am J Med Genet Part A 116A:1-10.
65. Cohen MM Jr. 2003b. Molecular dimensions of gastrointestinal tumors: Some thoughts for digestion. Am J Med Genet Part A 122A:303-314.
66. Cohen MM Jr. 2003c. The hedgehog signaling network. Am J Med Genet Part A 123A:5-28.
67. Cohen MM Jr. 2004. FGFs/FGFRs and associated disorders. From: Inborn Errors of Development. In: Epstein CJ, Erickson RP, Wynshaw-Boris A, editors. New York: Oxford University Press, Chapter 33, pp. 380-400.
68. Cohen MM Jr. 2006. Role of leptin in regulating appetite, neuroendocrine function, and bone remodeling. Am J Med Genet 140A:515-524.
69. Cohen MM Jr, Howell RE. 1999. Etiology of fibrous dysplasia and McCune-Albright syndrome. Int J Oral Maxillofac Surg 28:366-371.
70. Cohen MM Jr, MacLean RE. 2000. Craniosynostosis: Diagnosis, Evaluation and Management. Second Edition. New York: Oxford University Press.
71. Cohen RB, Hahn GV, Tabas JA, Peeper J, Levitz CL, Sando A, Sando N, Zasloff M, Kaplan FS. 1993. The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva: A study of 45 patients. J Bone Joint Surg 75A:215-219.
72. th Annual Meeting, San Francisco, California, October 19-23.
73. Cohen MM Jr, Neri G, Weksberg R. 2002. Overgrowth syndromes. New York: Oxford University Press.
74. Cole DEC, Cohen MM Jr. 1990. Mutations Affecting Bone-Forming Cells. In: Hall BK, editor. Bone: The osteoblast and osteocyte. Vol. 1. Caldwell, NJ: Telford Press, p. 431-487.
75. Collins MT, Shenker A. 1999. McCune-Albright syndrome: New insights. Endocrinol Diabetes 6:119-125.
76. Connor JM, Evans DAP. 1982. Genetic aspects of fibrodysplasia ossificans progressiva. J Med Genet 19:35-39.
77. Connor JM, Skirton H, Lunt PW. 1993. A three-generation family with fibrodysplasia ossificans progressiva. J Med Genet 30:687-689.
78. Conway JG, Wakefield JA, Brown RH, Marron BE, Sekut L, Stimpson SA, McElroy A, Menius JA, Jeffreys JJ, Clark RL, McGeehan GM, Connolly KM. 1995. Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor. J Exp Med 182:449-457.
79. Cook A, Raskind W, Blanton SH, Pauli RM, Gregg RG, Francomano CA, Puffenberger E, Conrad EU, Schmale G, Schellenberg G, Wijsman E, Hecht JT, Wells D, Wagner MJ. 1993. Genetic heterogeneity in families with hereditary multiple exostoses. Am J Hum Genet 53:71-79.
80. Dallas SL, Miyazono K, Skerry TM, Mundy GR, Bonewald LF. 1995. Dual role for the latent transforming growth factor beta binding protein (LTBP) in storage of latent TGFβ in the extracellular matrix and as a structural matrix protein. J Cell Biol 131:539-549.
81. Davidson D. 1995. The function and evolution of Msx genes: Pointers and paradoxes. Trends Genet 11:405-411.
82. De Beer GR. 1937. The Development of the Vertebrate Skull. London: Oxford University Press.
83. de Santa Barbara P, Bonneaud N, Boizet B, Desclozeaux M, Moniot B, Sudbeck P, Scherer G, Poulat F, Berta P. 1998. Direct interaction of SRY-related protein SOX9 and steroidogenic factor 1 regulates transcription of the human anti-Müllerian hormone gene. Mol Cell Biol 18:6653-6665.
84. DeLise AM, Fischer L, Tuan RS. 2000. Cellular interactions and signaling in cartilage development. Osteoarthritis and Cartilage 8:309-334.
85. den Hollander NS, van der Harten HJ, Vermeij-Keers C, Niermeijer MF, Wladimiroff JW. 1997. First-trimester diagnosis of Blomstrand lethal osteochondrodysplasia. Am J Med Genet 73:345-350.
86. Deutz-Terlouw PP, Losekoot M, Aalfs CM, Hennekam RC, Bakker E. 1998. Asn540Thr substitution in the fibroblast growth factor receptor 3 tyrosine kinase domain causing hypochondroplasia. Hum Mutat Suppl 1:562-565.
87. Dodé C, Levilliers J, Dupont J-M, De Paepe A, Le Dû N, Soussi-Yanicostas N. 2003. Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome. Nat Genet 33:463-465.
88. Dong J, Amor D, Aldred MJ, Gu T, Escamilla M, MacDougall M. 2005. DLX3 mutation associated with autosomal dominant amelogenesis imperfecta with taurodontism. Am J Med Genet 133A:138-141.
89. Duchatelet S, Ostergaard E, Cortes D, Lemainque A, Julier C. 2005. Recessive mutations in PTHR1cause contrasting skeletal dysplasias in Eiken and Blomstrand syndromes. Hum Mol Genet 14:1-5.
90. Ducy P, Starbuck M, Priemel M, Shen J, Pinero G, Geoffroy V, Amling M, Karsenty G. 1999. A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. Genes Dev 13:1025-1036.
91. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Biel FT, Shen J, Vinson C, Rueger JM, Karsenty G. 2000. Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass. Cell 100:197-207.
92. Dudding BA, Gorlin RJ, Langer LO Jr. 1967. The oto-palato-digital syndrome: A new symptom-complex consisting of deafness, dwarfism, cleft palate, characteristic facies, and a generalized bone dysplasia. Am J Dis Child 113:214-221.
93. Dunlop L-L T, Hall BK. 1995. Relationships between cellular condensation, preosteoblast formation and epithelial-mesenchymal interactions in initiation of osteogenesis. Int J Dev Biol 39:357-371.
94. Ebeling PR, Erbas B, Hopper JL, Wark JD, Rubinfeld AR. 1998. Bone mineral density and bone turnover in asthmatics treated with long-term inhaled or oral glucocorticoids. J Bone Miner Res 13:1283-1289.
95. Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang X, Liu X, Condo H, Richards WG, Bannon TW, Noda M, Clement K, Vaisse C, Karsenty G. 2005. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434:514-520.
96. Elmquist JK, Strewler GJ. 2005. Do neural signals remodel bone? Nature 434:447-448.
97. Enomoto H, Enomoto-Iwamoto M, Iwamoto M, Nomura S, Himeno M, Kitamura Y, Kishimoto T, Komori T. 2000. Cbfa1 is a positive regulatory factor in chondrocyte maturation. J Biol Chem 275:8695-8702.
98. Entesarian M, Matsson H, Klar J, Bergendal B, Olson L, Arakaki R, Hayashi Y, Ohuchi H, Falahat B, Bolstad AI, Jonsson R, Wahren-Herlenius M, Dahl N. 2005. Mutations in the gene encoding fibroblast growth factor 10 are associated with aplasia of lacrimal and salivary glands. Nat Genet 37:125-128.
99. Erlebacher A, Filvaroff EH, Gitelman SE, Derynck R. 1995. Toward a molecular understanding of skeletal development. Cell 80:371-378.
100. Faglia G, Arosio M, Spada A. 1996. GS protein mutations and pituitary tumors: Functional correlates and possible therapeutic implications. Metabolism 45:117-119.
101. Fang J, Hall BK. 1997. Chondrogenic cell differentiation from membrane bone priostea. Anat Embryol 196:349-362.
102. Finch PW, He X, Kelley MJ, Uren A, Schaudies RP, Popescu NC, Rudikoff S, Aaronson SA, Varmus HE, Rubin JS. 1997. Purification and molecular cloning of a secreted, frizzled-related antagonist of Wnt action. Proc Natl Acad Sci USA 94:6770-6775.
103. Firestein GS. 2003. Evolving concerpts of rheumatoid arthritis. Nature 423:356-361.
104. Fox JW, Lamperti ED, Eksioglu YZ, Hong SE, Feng Y, Graham DA, Scheffer IE, Dobyns WB, Hirsch BA, Radtke RA, Berkovic SF, Huttenlocher PR, Walsh CA. 1998. Mutations in filamin 1 prevent migration of cerebral cortical neurons in human periventricular heterotopia. Neuron 21:1315-1325.
105. Frattini A, Orchard PJ, Sobacchi C, Giliani S, Abinun M, Mattsson JP, Keeling DJ, Andersson A-K, Wallbrandt P, Zecca L, Notarangelo LD, Vezzoni P, Villa A. 2000. Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nat Genet 25:343-346.
106. Fraumeni JF Jr. 1967. Stature and malignant tumors of bone in childhood and adolescence. Cancer 20:967-973.
107. Fujino TH, Asaba H, Kang MJ, Ikeda Y, Sone H, Takada S, Kim DH, Ioka RX, Ono M, Tomoyori H, Okubo M, Murase T, Kamataki A, Yamamoto J, Magoori K, Takahashi S, Miyamoto Y, Oishi H, Nose M, Okazaki M, Usui S, Imaizumi K, Yanagisawa M, Sakai J, Yamamoto TT. 2003. Low-density lipoprotein-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucose-induced insulin secretion. Proc Natl Acad Sci USA 100:229-234.
108. Galibert L, Tometsko ME, Anderson DM, Cosman D, Dougall WC. 1998. The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily. J Biol Chem 273: 34, 120-127.
109. Gao B, Guo J, She C, Shu A, Yang M, Tan Z, Yang X, Guo S, Feng G, He L. 2001. Mutations in IHH, encoding Indian hedgehog, cause brachydactyly type A-1. Nat Genet 28:386-388.
110. Garrington GE, Schofield HH, Cornyn J, Hooker SP. 1967. Osteosarcoma of the jaws. Cancer 20:377-391.
111. Geoffroy V, Kneissel M, Fournier B, Boyde A, Mathias P. 2002. High bone resorption in adult aging transgenic mice overexpressing cbfa1/runx2 in cells of the osteoblastic lineage. Mol Cell Biol 22:6222-6233.
112. Giguère Y, Rousseau F. 2000. The genetics of osteoporosis: 'Complexities and difficulties.' Clin Genet 57:161-169.
113. Givol D, Yayon A. 1992. Complexity of FGF receptors: Genetic basis for structural diversity and functional specificity. FASEB J 6:3362-3369.
114. Glass DA, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA, Karsenty G. 2005. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8:751-764.
115. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marceline J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GCM, Boles RG, Boon LM, Barrone C, Brunner HG, Carle GF, Dallapiccola B, De Paepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Jüppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, LaCombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, van den Boogaard M-J, Van Hul W, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR, Warman ML. 2001. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107:513-523.
116. Goriely A, McVean GAT, Röjmyr M, Ingemarsson B, Wilkie AOM. 2003. Evidence for selective advantage of pathogenic FGFR2 mutations in the male germ line. Science 301:643-646.
117. Goriely A, McVean GAT, van Pelt AMM, O'Rourke AW, Wall SA, de Rooji DG, Wilkie AOM. 2005. Gain-of-function amino acid substitutions drive positive selection of FGFR2 mutations in human spermatogonia. PNAS 17:6051-6056.
118. Gorlin RJ, Cohen MM Jr. 1969. Frontometaphyseal dysplasia: A new syndrome. Am J Dis Child 118:487-494.
119. Gorlin JB, Yamin R, Egan S, Stewart M, Stossel TP, Kwiatkowski DJ, Hartwig JH. 1990. Human endothelial actin-binding protein (ABP-280, nonmuscle filamin): A molecular leaf spring. J Cell Biol 111:1089-1105.
120. Gorlin JB, Henske E, Warren ST, Kunst CB, D'Urso M, Palmieri G, Hartwig JH, Bruns G, Kwiatkowski DJ. 1993. Actin-binding protein (AB-280) filamin gene (FLN) maps telomeric to the color vision locus (R/GCP) and centromeric to G6PD in Xq28. Genomics 17:496-498.
121. Gorlin RJ, Cohen MM Jr, Hennekam RCM. 2001. Syndromes of the Head and Neck. Fourth Edition. New York: Oxford University Press.
122. Graber LW. 1978. Congenital absence of teeth: A review with emphasis on inheritance patterns. J Am Dent Assoc 96:266-275.
123. Grigelioniene G, Hagenas L, Eklof O, Neumeyer L, Haerid PE, Anvret M. 1998. A novel missense mutation Ile538Val in the fibroblast growth factor receptor 3 in hypochondroplasia. Hum Mutat 11:333.
124. Grigelioniene G, Eklof O, Aurencikas E, Ollars B, Hertel NT, Dumanski JP, Hagenas L. 2000. The Asn540Lys mutation in FGR3 and phenotype in hypochondroplasia. Acta Paediatr 89:1072-1076.
125. Grigoriadis AE, Heersche JN, Aubin JE. 1988. Differentiation of muscle, fat, cartilage, and bone from progenitor cells present in a bone-derived clonal cell population: Effect of dexamethasone. J Cell Biol 106:2139-2151.
126. Guo X, Day TF, Jiang X, Garrett-Beal L, Topol L, Yang Y. 2004. Wnt/beta-catenin signaling is sufficient and necessary for synovia! joint formation. Genes Dev 18:2404-2417.
127. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, Burley SK, Friedman JM. 1995. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269:543-546.
128. Hall BK. 1967a. The distribution and fate of adventitious cartilage in the skull of the eastern rosella, Platycercus eximus. Aust J Zool 15:685-698.
129. Hall BK. 1967b. The formation of adventitious cartilage by membrane bones under the influence of mechanical stimulation applied in vitro. Life Sci 6:663-667.
130. Hall BK. 1970. Cellular differentiation in skeletal tissues. Biol Rev 45:455.
131. Hall BK. 1997. Bone, embryonic development. In Encyclopedia of Human Biology. Vol. 2, Second Edition. New York: Academic Press, pp. 105-114.
132. Hall BK. 2005. Bones and Cartilage: Development and Evolutionary Skeletal Biology. San Diego: Elsevier.
133. Hall BK, Miyake T. 1992. The membranous skeleton: The role of cell condensations in vertebrate skeletogenesis. Anat Embryol 186:107-124.
134. Hall BK, Miyake T. 1995. Divide, accumulate, differentiate: Cell condensation in skeletal development revisited. Int J Dev Biol 39:881-893.
135. Hall BK, Miyake T. 2000. All for one and one for all: Condensations and the initiation of skeletal development. BioEssays 22:138-147.
136. Hall BD, Spranger JW. 1980. Campomelic dysplasia: Further elucidation of a distinct entity. Am J Dis Child 134:285-289.
137. Hall CR, Cole WG, Haynes R, Hecht JT. 2002. Reevaluation of a genetic model for the development of exostosis in hereditary multiple exostosis. Am J Med Genet 112:1-5.
138. Hanai J, Chen LF, Kanno T, Ohtani-Fujita N, Kim W-Y, Guo W-H, Imamura T, Ishidou Y, Fukuchi M, Shi M-J, Stavnezer J, Kawabata M, Miyazono K, Ito Y. 1999. Interaction and functional cooperation of PEBP2/CBF with Smads: Syndrgistic induction of the immunoglobulin germline Cα promoter. J Biol Chem 274:31577-31582.
139. Happle R. 1986. The McCune-Albright syndrome: A lethal gene surviving by mosaicism. Clin Genet 29:321-324.
140. Harris PE. 1996. Gs protein mutations and the pathogenesis and function of pituitary tumors. Metabolism 45:120-122.
141. Hartmann C, Tabin CJ. 2001. Wnt-14 plays a pivotal role in inducing synovial joint formation in the developing appendicular skeleton. Cell 104:341-351.
142. Hayward BE, Moran V, Strain L. 1998. Bidirectional imprinting of a single gene: GNAS1 encodes maternally, paternally, and biallelically derived proteins. Proc Natl Acad Sci USA 95:1575-15780.
143. Hecht JT, Hogue D, Strong LC, Hansen MF, Blanton SH, Wagner M. 1995. Hereditary multiple exostosis and chondrosarcoma: Linkage to chromosome 11 and loss of heterozygosity for EXT-linked markers on chromosomes 11 and 8. Am J Hum Genet 56:1125-1131.
144. Hecht JT, Hogue D, Wang Y, Blanton SH, Wagner M, Strong LC, Rasking W, Hansen MF, Wells D. 1997. Hereditary multiple exostoses (EXT): Mutational studies of familial EXT1 cases and EXT-associated malignancies. Am J Hum Genet 60:80-86.
145. Hellemans J, Coucke PJ, Giedion A, De Paepe A, Kramer P, Beemer F, Mortier GR. 2003. Homozygous mutations in IHH cause acrocapitofemoral dysplasia, an autosomal recessive disorder wth cone-shaped epiphyses in hands and hips. Am J Hum Genet 72:1040-1046.
146. Héon E, Sheth BP, Kalenak JW, Sunden SL, Streb LM, Taylor CM, Alward WLM, Sheffield VC, Stone EM. 1995. Linkage of autosomal dominant iris hypoplasia to the region of Rieger syndrome locus (4q25). Hum Mol Genet 4:1435-1439.
147. Hermanns P, Lee B, 2001. Transcriptional dysregulation in skeletal malformation syndromes. Am J Med Genet (Semin Med Genet) 106:258-271.
148. Hewitt JE, Clark LN, Ivens A, Williamson R. 1991. Structure and sequence of the human homeobox gene HOX 7. Genomics 11:670-678.
149. Hill RE, Jones PF, Rees AR, Sime CM, Justice MJ, Copeland NG, Jenkins NA, Graham E, Davidson DR. 1989. A new family of mouse homeobox-containing genes: Molecular structure, chromosomal location, and developmental expression of Hox7.1. Genes Dev 3:26-27.
150. Hill TP, Später D, Taketo MM, Birchmeier W, Hartmann C. 2005. Canonical Wnt/β-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell 8:727-738.
151. Hinton DR, Becker LE, Muakkassa KF, Hoffman HJ. 1984. Lambdoid synostosis. Part 1: The lambdoid suture: Normal development and pathology of "synostosis". J Neurosurg 61:333-339.
152. Hocking LJ, Herbert CA, Nicholls RK, Williams F, Bennett ST, Cundy T, Nicholson GC, Wuyts W, Van Hul W, Ralston SH. 2001. Genomewide search in familial Paget disease of bone shows evidence of genetic heterogeneity with candidate loci on chromosomes 2q36, 10p13, and 5q35. Am J Hum Genet 69:1055-1061.
153. Hogan BLM. 1996. Bone morphogenetic proteins: Multifunctional regulators of vertebrate development. Genes Dev 10:1580-1594.
154. Holland PWH. 1991. Cloning and evolutionary analysis of msh like homeobox genes from mouse, zebrafish and ascidian. Gene 98:253-257.
155. Holmen SL, Zylstra CR, Mukherjee A, Sigler RE, Faugere M-C, Bouxsein ML, Deng L, Clemens TL, Williams BO. 2005. Essential role of β-catenin in postnatal bone acquisition. J Biol Chem 280:21162-21168.
156. Hopyan S, Gokgoz N, Poon R, Gensure RC, Yu C, Cole WG, Bell RS, Juppner H, Andrulis IL, Wunder JS, Alman BA. 2002. A mutant PTH/PTHrP type I receptor in enchondromatosis. Nat Genet 30:306-310.
157. Horton WA. 1990. The biology of bone growth. Growth, Genetics, and Hormones 6:1-5.
158. Houston CS, Opitz JM, Spranger JW, Macpherson RI, Reed MH, Gilbert EF, Herrmann J, Schinzel A. 1983. The campomelic syndrome: Review, report of 17 cases, and follow-up on the currently 17-year-old boy first reported by Maroteaux et al in 1971. Am J Med Genet 15:3-28.
159. Hu G, Vastardis H, Bendall AJ, Wang Z, Logan M, Zhang H, Nelson C, Stein S, Greenfield N, Seidman CE, Seidman JG, Abate-Shen C. 1998. Haploinsufficiency of MSX1: A mechanism for selective tooth agenesis. Mol Cell Biol 18:6044-6051.
160. Hu H, Hilton MJ, Tu X, Yu K, Ornitz D, Long F. 2005. Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development 132:49-60.
161. Huang L-F, Fukal N, Selby PB, Olsen BR, Mundlos S. 1997. Mouse clavicular development: Analysis of wild-type and deidocranial dysplasia mutant mice. Dev Dynamics 210:33-40.
162. Huang N, Pandey AV, Reardon W, Lapunzina PD, Mowat D, Jabs EW, Van Vliet G, Sack J, Flück CE, Miller WL. 2005. Diversity and function of mutations in P450 oxidoreductase in patients with Antley-Bixler syndrome. Am J Hum Genet 76:729-749.
163. Hughes AE, Ralston SH, Marken J, Bell C, MacPherson H, Wallace RGH, van Hul W, Whyte MP, Nakatsuka K, Hovy L, Anderson DM. 2000. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet 24:45-48.
164. Inada M, Yasui T, Nomura S, Miyake S, Deguchi K, Himeno M, Sato M, Yamagawa H, Kimura T, Yasui N, Ochi T, Endo N, Kitamura Y, Kishimoto T, Komori T. 1999. Maturational disturbance of chondrocytes in Cbfa1deficient mice. Dev Dynamics 214:279-290.
165. Ingham PW. 1996. Has the quest for a Wnt receptor finally frizzled out? Trends Genet 12:382-384.
166. International Nosology and Classification of Constitutional Disorders of Bone. 2003.
167. Ito Y. 1999. Molecular basis of tissue-specific gene expression mediated by the Runt domain transcription factor PEBP2/CBF. Genes Cells 4:685-696.
168. Ito Y, Bae S-C. 1997. The runt domain transcription factor, PEBP2/ CBF, and its involvement in human leukemia. In: Karin M, editor. Progress in Gene Expression. Basel, Switzerland: Birkhäuser Verlag, pp. 107-132.
169. Itoh S, Itoh F, Goumans M-J, ten Dijke P. 2000. Signaling of transforming growth factor-β family members through Smad proteins. Eur J Biochem 267:6954-6967.
170. Ivens A, Flavin A, Williamson R, Dixon M, Bates G, Buckingham M, Robert B. 1990. The human homeobox gene HOX7 maps to chromosome 4p16.1 and may be implicated in Wolf-Hirschorn syndrome. Hum Genet 84:473-476.
171. Jabs EW, Müller U, Li X, Ma I, Luo W, Haworth IS, Kisak I, Sparkes R, Warman ML, Mulliken JB, Snead ML, Maxson R. 1993, A mutation in the homeodomain of the human MSX2gene in a family affected with autosomal dominant craniosynostosis. Cell 75:443-450.
172. Jan de Beur S, O'Connell JR, Peila R, Cho J, Deng Z, Kam S, Levine MA. 2003. The pseudohypoparathyroidism type 1b locus is linked to a region including GNAS1 at 20q13.3. J Bone Miner Res 18:424-433.
173. Janssens K, Gershoni-Baruch R, Guanabens N, Migone N, Ralston S, Bonduelle M, Lissens W, Van Maldergem L, Vanhoenacker F, Verbruggen L, Van Hul W. 2000. Mutations in the gene encoding the latency-associated peptide of TGF-beta 1 cause Camurati-Engelmann disease. Nat Genet 26:273-275.
174. Jaskoll T, Luo W, Snead ML. 1998. Msx-2 expression and glucocorticoid-induced overexpression in embryonic mouse submandibular glands. J Craniofac Genet Dev Biol 18:79-87.
175. Jernvall J, Thesleff I. 2000. Reiterative signaling and patterning in mammalian tooth morphogenesis. Mech Dev 92:19-29.
176. Jiang X, Iseki S, Maxson RE, Sucov HM, Morriss-Kay GM. 2002. Tissue origins and interactions in the mammalian skull vault. Dev Bio 241:106-116.
177. Jimenez MJ, Balbin M, Lopez JM, Alvarez J, Komori T, Lopez-Otin C. 1999. Collagenase-3 is a target of Cbfa1, a transcription factor of the runt gene family involved in bone formation. Mol Cell Biol 19:4431-4442.
178. Jobert A-S, Zhang P, Couvineau A, Bonaventure J, Roume J, Le Merrer M, Silve C. 1998. Absence of functional receptors for parathyroid hormone and parathyroid hormone-related peptide in Blomstrand chondrodysplasia. J Clin Invest 102:34-40, 1998.
179. Johnson DE, Williams LT. 1993. Structural and functional diversity in the FGF receptor and multigene family. Adv Cancer Res 60:1-41.
180. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljuggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Jüppner H. 2003. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656-1661.
181. Jowett AK, Vainio S, Ferguson MW, Sharpe PT, Thesleff I. 1993. Epithelial-mesenchymal interactions are required for MSX1 and MSX2 gene expression in the developing murine molar tooth. Development 117:461-470.
182. Jumlongras D, Bei M, Stimson JM, Wang W-F, DePalma SR, Seidman CE, Felbor U, Maas R, Seidman JG, Olsen BR. 2001. A nonsense mutation in MSX1 causes Witkop syndrome. Am J Hum Genet 69:67-74.
183. Jüppner H, Schipani E, Bastepe M. 1998. The gene responsible for pseudohypoparathyroidism type Ib is paternally imprinted and maps in four unrelated kindreds to chromosome 20q13.3. Proc Natl Acad Sci USA 95:1178-1180.
184. Kaartinen V, Warburton D. 2003. Fibrillin controls TGF-β activation. Nat Genet 33:331-332.
185. Kadler KE. 1995. Extracellular matrix 1: Fibril-forming collagens. Protein Profile 2:491-619.
186. Kan S-h, Elanko N, Johnson D, Cornejo-Roldan L, Cook J, Reich EW, Tomkins S, Verloes A, Twigg SRF, Ranan-Eliya S, Wilkie AOM. 2002. Genomic screening of fibroblast growth factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosis. Am J Hum Genet 70:472-486.
187. Kaplan FS, Tabas JA, Gannon FH, Finkel G, Hahn GV, Zasloff M. 1993. The hitopathology of fibrodysplasia ossificans progressiva: An endochondral process. J Bone Joint Surg 75A:220-230.
188. Kaplan FS, Graver R, MacEwen GD, Gannon FH, Finkel G, Hahn G, Tabas J, Gardner RJM, Zasloff MA. 1994. Progressive osseous heteroplasia: Two new case reports and follow-up of three previously reported cases. J Bone Joint Surg 76A:425-436.
189. Karaplis AC, He B, Nguyen MTA, Young ID, Semeraro D, Ozawa H, Amizuka N. 1998. Inactivating mutation in the human parathyroid hormone receptor type 1 gene in Blomstrand chondrodysplasia. Endocrinology 139:5255-5258.
190. Karperien M, van der Harten HJ, van Schooten R, Farih-Sips H, den Hollander NS, Kneppers SLJ, Nijweide P, Papapoulos SE, Lowik CWGM. 1999. A frame-shift mutation in the type I parathyroid hormone (PTH)/PTH-related peptide receptor causing Blomstrand lethal osteochondrodysplasia. J Clin Metab 84:3713-3720.
191. Karsenty G. 1999. The genetic transformation of bone biology. Genes Dev 13:3037-3051.
192. Kawakami Y, Tsuda M, Takahashi S, Taniguchi N, Rodriguez Esteban C, Zemmyo M, Furumatsu T, Lotz M, Belmonte JCI, Asahara H. 2005. Transcriptional coactivator PGC-1α regulates chondrogenesis via association with Sox9. Proc Natl Acad Sci USA 102:2414-2419.
193. Kengaku M, Capdevila J, Rodriguez-Esteban C, De La Peña J, Johnson RL, Belmonte JC, Tabin CJ. 1998. Distinct WNT pathway regulating AER formation and dorsoventral polarity in the chick limb bud. Science 280:1274-1277.
194. Kere J, Srivastava AK, Montonen O, Zonana J, Thomas N, Ferguson B, Muñoz F, Morgan D, Clarke A, Baybayan P, Chen EY, Ezer S, Saarialho-Kere U, de la Chapelle A, Schlessinger D. 1996. X-linked anhidrotic (hypohidrotic) ectodermal dysplasia is caused by mutation in a novel transmembrane protein. Nat Genet 13:409-416.
195. Kim H-J, Rice DPC, Kettunen PJ, Thesleff I. 1998. FGF-, BMP- and Shh-mediated signaling pathways in the regulation of cranial suture morphogenesis and calvarial bone development. Development 125:1241-1251.
196. Kingsley DM. 1994a. The TGF-β superfamily: New members, new receptors, and new genetic tests of function in different organisms. Genes Dev 8:133-146.
197. Kingsley DM. 1994b. What do BMPs do in mammals? Clues from the mouse short-ear mutation. Trends Genet 10:16-21.
198. Kinoshita A, Saito T, Tomita H, Makita Y, Yoshida K, Ghadami M, Yamada K, Kondo S, Ikegawa S, Nishimura G, Fukushima Y, Nakagomi T, Saito H, Sugimoto T, Kamegaya M, Hisa K, Murray JC, Taniguchi N, Niikawa N, Yoshiura K. 2000. Domain-specific mutations in TGFβ1 result in Camurati-Engelmann disease. Nat Genet 26:19-20.
199. Kinoshita A, Fukumaki Y, Shirahama S, Miyahara A, Nishimura G, Haga N, Namba A, Ueda H, Hayashi H, Ikegawa S, Seidel J, Niikawa N, Yoshiura K-i. 2004. TGFβ1 mutations in four new families with Camurati-Engelmann disease: Confirmation of independently arising LAP-domain-specific mutations. Am J Med Genet Part A 127A:104-107.
200. Kirkpatrick TJ, Au K-S, Mastrobattista JM, McCready ME, Bulman DE, Northrup H. 2003. Identification of a mutation in the Indian hedgehog (IHH) gene causing brachydactyly type A1 and evidence for a third locus. J Med Genet 40:42-44.
201. Kitoh H, Brodie SG, Kupke KG, Lachman RS, Wilcox WR. 1998. Lys650Met substitution in the tyrosine kinase domain of the fibroblast growth factor receptor 3 gene causes thanatophoric dysplasia type I. Hum Mutat 12:362-363.
202. Komori T, Kishimoto T. 1998. Cbfa1 in bone development. Curr Opin Genet Dev 8:494-499.
203. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao Y-H, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S, Kishimoto T. 1997. Targeted disruption of cbfal results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89:755-764.
204. Kong Y-Y, Yoshida H, Sarosi I, Tan H-L, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM. 1999. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323.
205. +-ATPase cause infantile malignant osteopetrosis. Hum Mol Genet 9:2059-2063.
206. Kornak U, Kasper D, Bösl MR, Kaiser E, Schweizer M, Schulz A, Friedrich W, Delling G, Jentsch TJ. 2001. Loss of the CIC-7 chloride channel leads to osteopetrosis in mice and man. Cell 104:205-215.
207. Kristensen P, Judge ME, Thim L, Ribel U, Christjansen KN, Wulff BS, Clausen JT, Jensen PB, Madsen OD, Vrang N, Larsen PJ, Hastrup S. 1998. Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 393:72-76.
208. Kundu M, Javed A, Jeon J-P, Horner A, Shum L, Eckhaus M, Muenke M, Lian JB, Yang Y, Nuckolls GH, Stein GS, Liu PP. 2002. Cbfbeta interacts with Runx2 and has a critical role in bone development. Nat Genet 32:639-644.
209. 2+ pathway: A new vertebrate Wnt signaling pathway takes shape. Trends Genet 16:279-282.
210. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian Y-X, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
211. Lammi L, Arte S, Somer M, Jarvinen H, Lahermo P, Thesleff I, Pirinen S, Nieminen P. 2004. Mutations in AXIN2 cause familial tooth agenesis and predisposes to colorectal cancer. Am J Hum Genet 74:1043-1050.
212. a and stimulate adenylyl cyclase in human pituitary tumours. Nature 340:692-696.
213. Lanske B, Karaplis AC, Lee K, Luz Z, Vortkamp A, Pirro A, Karperien M, Defize LHK, Ho C, Mulligan RC, Abou-Samra A-B, Jüppner H, Segre GV, Kronenberg HM. 1996. PTH/PTHrP receptor in early development and Indian hedgehog-regulated bone growth. Science 273:663-666.
214. Lee B, Thirunavukkarasu K, Zhou I, Pastore I, Baldini A, Hecht J, Geoffroy V, Ducy P, Karsenty G. 1997. Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1. Nat Genet 16:307-310.
215. Legeai-Mallet L, Rossi A, Benoist-Lasselin C, Piazza R, Mallet J-F, Delezoide A-L, Munnich A, Bonaventure J, Zylberberg L. 2000. EXT 1 gene mutation induces chondrocyte cytoskeletal abnormalities and defective collagen expression in the exostoses. J Bone Miner Res 15:1489-1500.
216. Levine MA, Modi WS, O'Brien SJ. 1991. Mapping of the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase (GNAS1) to 20q13.2-q13.3 in human by in situ hybridization. Genomics 11:478-479.
217. Lidral AC, Reising BC. 2002. The role of MSX1 in human tooth agenesis. J Dent Res 81:274-278.
218. Linglart A, Gensure RC, Olney RC, Jüppner H, Bastepe M. 2005. A novel STX16 deletion in autosomal dominant pseudohypoparathyroidism type Ib redefines the boundaries of a exacting imprinting control element of GNAS. Am J Hum Genet 76:804-814.
219. Little BB, Knoll KA, Klein VR, Heller KB. 1990. Hereditary cranium bifidum and symmetric parietal foramina are the same entity. Am J Med Genet 35:453-458.
220. Liu YH, Kundu R, Wu L, Luo W, Ignelzi MA Jr, Snead ML, Maxson RE Jr. 1995. Premature suture closure and ectopic cranial bone in mice expressing Msx2 transgenes in the developing skull. Proc Natl Acad Sci USA 92:6137-6141.
221. Locksley RM, Killeen N, Lenardo MJ. 2001. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 104:487-501.
222. Loshkajian A, Roume J, Stanescu V, Delezoide A, Stampf F, Maroteaux P. 1997. Familial Blomstrand chondrodysplasia with advanced skeletal maturation: Further delineation. Am J Med Genet 71:283-288.
223. Luckert-Wicklund C, Pauli RM, Johnston D, Hecht JT. 1995. Natural history study of hereditary multiple exostoses. Am J Med Genet 55:43-46.
224. Lucotte G, Sémonin O, Lutz P. 1999. Letter to the editor. A de novo heterozygous deletion of 42 base-pairs in the noggin gene of a fibrodysplasia ossificans progressiva patient. Clin Genet 56:469-470.
225. Luder HV, Steinmann B. 1997. Teeth in osteogenesis imperfecta: A mirror of genetic collagen defects? In: Cohen MM, Jr., Baum BJ, editors. Studies in Stomatology and Craniofacial Biology. Amsterdam: IOS Press, Chap. 13, pp. 209-228.
226. Lum L, Beachy PA. 2004. The Hedgehog response network: Sensors, switches, and routers. Science 304:1755-1759.
227. Magoori K, Kang MJ, Ito MR, Kakuuchi H, Ioka RX, Kamataki A, Kim DH, Asaba H, Iwasaki S, Takei YA, Sasaki M, Usui S, Okazaki M, Takahashi S, Ono M, Nose M, Sakai J, Fujino T, Yamamoto TT. 2003. Severe hypercholesterolemia, impaired fat tolerance, and advanced atherosclerosis in mice lacking both low density lipoprotein receptor-related protein 5 and apolipoprotein. Eur J Biol Chem 278:11331-11336.
228. + T-cells trigger RANKL-mediated enhanced alveolar bone loss in diabetic NOD mice. Diabetes 54:1477-1486.
229. Malchoff CD, Reardon G, MacGillivrary DC, Yamase H, Rogol AD, Malchoff DM. 1994. An unusual presentation of McCune-Albright syndrome confirmed by an activating mutation of the G(s) alpha-subunit from a bone lesion. J Clin Endocrinol Metab 78:803-806.
230. Mansour S, Hall CM, Pembrey ME, Young ID. 1995. A clinical and genetic study of campomelic dysplasia. J Med Genet 32:415-420.
231. Mao J, Wang J, Liu B, Pan W, Farr GH, Flynn C, Yuan H, Takeda S, Kimelman D, Li L, Wu D. 2001. Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. Mol Cell 7:801-809.
232. Maroteaux P, Spranger JW, Opitz JM, Kucera J, Lowry RB, Schimke RN, Kagan SM. 1971. Le syndrome campomelique. Presse Med 22:1157-1162.
233. Marx J. 2004. Coming to grips with bone loss. Science 305:1420-1422.
234. Mason I. 1994. The ins and outs of fibroblast growth factors. Cell 78:547-552.
235. Massagué J. 1998. TGFβ signal transduction. Annu Rev Biochem 67:753-791.
236. Massagué J, Wotton D. 2000. Transcriptional control by the TGFβ/ Smad signaling system. EMBO J 19:1745-1754.
237. Massagué J, Attisano L, Wrens JL. 1994. The TGF-β family and its composite receptors. Trends Cell Biol 4:173-178.
238. McCormick C, Leduc Y, Martindale D, Mattison K, Esford LE, Dyer AP, Tufaro F. 1998. The putative tumour suppressor EXT1 alters the expression of cell-surface heparan sulfate. Nat Genet 19:158-161.
239. McCready ME, Sweeney E, Fryer AE, Donnai D, Baig A, Racacho L, Warman ML, Hunter AGW, Bulman DE. 2002. A novel mutation in the IHH gene causes brachydactyly type A1: A 95-year-old mystery resolved. Hum Genet 111:368-375.
240. McLarren KW, Lo R, Grbavec D, Thirunavukkarasu K, Karsenty G, Stifani S. 2000. The mammalian basic helix loop helix protein HES-1 binds to and modulates the transactivating function of the runt-related factor Cbfal. J Biol Chem 275:530-538.
241. Melton LJ, Achenbach SJ, O'Fallon WM, Khosla S. 2002. Secondary osteoporosis and the risk of distal forearm fractures in men and women. Bone 31:119-125.
242. Merrill AE, Bochukova EG, Brugger SM, Ishii M, Pilz DT, Wall SA, Lyons KM, Wilkie AOM, Maxson RE Jr. 2006. Cell mixing at a neural crest-mesoderm boundary and deficient ephrin-Eph signaling in the pathogenesis of craniosynostosis. Hum Mol Genet 15:1319-1328.
243. 2+ pathways. Oncogene 18:7860-7872.
244. Miller J, Horner A, Stacy T, Lowrey C, Lian JB, Stein G, Nuckolls GH, Speck NA. 2002. The core-binding factor beta subunit is required for bone formation and hematopoietic maturation. Nat Genet 32:645-649.
245. Miyake S, Shintaro JM, Sato M, Iwamoto T, Ohmori T, Kishimoto T, Komori T. 1998. Analysis of the tooth development in Cbfa1-deficient mice. J Bone Min Metab 16:32.
246. Miyazono K, Hellman U, Wernstedt C, Heldin CH. 1988. Latent high molecular weight complex of transforming growth factor β1. Purification from human platelets and structural characterization. J Biol Chem 263:6407-6415.
247. Miyazono K, Olofsson A, Colosetti P, Heldin CH. 1991. A role of latent TGF-beta 1-binding protein in the assembly and secretion of TGF-beta 1. EMBO J 10:1091-1101.
248. Miyazono K, ten Duke P, Heldin C-H. 2000. TGF-β signaling by Smad proteins. Adv Immunol 75:115-157.
249. Moog U, Jansen NJG, Scherer G, Schrander-Stempel CTRM. 2001. Acampomelic campomelic syndrome. Am J Med Genet 104:239-245.
250. Moon RT, Brown JD, Torres M. 1997. WNTs modulate cell fate and behavior during vertebrate development. Trends Genet 13:157-162.
251. Moren A, Olofsson A, Stenman G, Sahlin P, Kanzaki T, Claesson-Welsh L, ten Diijke P, Miyazono K, Heldin CH. 1994. Identification and chacterization of LTBP-2, a novel latent transforming growth factor β binding protein. J Biol Chem 269:32469-32478.
252. Moro F, Carrozzo R, Veggiotti P, Tortorella G, Toniolo D, Volzone A, Guerrini R. 2002. Familial periventricular heterotopia: Missense and distal truncating mutations of the FLN1 gene. Neurology 58:916-921.
253. Mortier G, Nuytinck L, Craen M, Renard J-P, Leroy JG, De Paepe A. 2000. Clinical and radiographic features of a family with hypochondroplasia owing to a novel Asn540Ser mutation in the fibroblast growth factor receptor 3 gene. J Med Genet 37:220-224.
254. Mortier GR, Kramer PPG, Giedion A, Beemer FA. 2003. Acrocapitofemoral dysplasia: An autosomal recessive skeletal dysplasia with cone shaped epiphyses in the hands and hips. J Med Genet 40:201-207.
255. Mostov K, Werb Z. 1997. Journey across the osteoclast. Science 276:219-220.
256. Muenke M, Francomano CA, Cohen MM Jr, Jabs EW. 1998. Fibroblast growth factor receptor-related skeletal disorders. In: Jameson JL, editor. Principles of molecular medicine. Totowa, NJ: Humana Press, pp. 1029-1038.
257. Mundlos S. 1999. Cleidocranial dysplasia: Clinical and molecular genetics. J Med Genet 36:177-182.
258. Mundlos A, Otto F, Mundlos C, Mulliken JB, Aylsworth AS, Albright S, Lindhout D, Cole WG, Henn W, Knoll JHM, Owen MJ, Mertelsmann R, Zabel BU, Olsen BR. 1997. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell 89:773-779.
259. Muñoz F, Lestringant G, Sybert V, Frydman M, Alswaini A, Frossard PM, Jorgenson R. 1997. Definitive evidence for an autosomal recessive form of hypohidrotic ectodermal dysplasia clinically indistinguishable from the more common X-linked disorder. Am J Hum Genet 61:94-100.
260. Monreal AX, Zonana J, Ferguson B. 1998. Identification of a new splice form of the EDA1 gene permits detection of nearly all X-linked hypohidrotic ectodermal dysplasia mutations. Am J Hum Genet 63:380-389.
261. Müller U, Warman ML, Mulliken JB, Weber JL. 1993. Assignment of a gene locus involved in craniosynostosis to chromosome 5qter. Hum Mol Genet 2:119-122.
262. 2+ and calmodulin regulate the binding of filamin A to actin filaments. J Biol Chem 280:32426-32433.
263. Nakashima K, de Crombrugghe B. 2003. Transcriptional mecha3 nisms in osteoblast differentiation and bone formation. Trends Genet 19:458-466.
264. Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR, de Crombrugghe B. 2002. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108:17-29.
265. Nathrath MH, Kuosaite V, Rosemann M, Kremer M, Poremba C, Wakana S, Yanagi M, Nathrath WBJ, Höfler H, Imai K, Atkinson MJ. 2002. Two novel tumor suppressor gene loci on chromosome 6q and 15q in human osteosarcoma identified through comparitive study of allelic imbalances in mouse and man. Oncogene 21:5975-5980.
266. Nellissery M, Padalecki SS, Brkanac Z, Singer FR, Roodman GD, Unni KK, Leach RJ, Hansen MF. 1998. Evidence for a novel osteosarcoma tumor-suppressor gene in the chromosome 18 region genetically linked with Paget disease of bone. Am J Hum Genet 63:817-824.
267. Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, Ramirez F, Sakai LY, Dietz HC. 2003. Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome. Nat Genet 33:407-411.
268. Newberry EP, Latifi T, Battaile JT, Towler DA. 1997. Structure-function analysis of Msx2-mediated transcriptional suppression. Biochemistry 36:10451-10462.
269. Neil J, Cameron E, Stewart M, Blyth K, Vaillant F, Ming H, Terry A, Mackay N, Bell B. 2000. In vito and in vitro analysis of Cbfa1/ Runx2 oncogenic functions. International Workshop on Runt-Domain Transcription Factors, Kyoto, Japan.
270. Nollet F, Berx G, Molemans F, van Roy F. 1996. Genomic organization of the human beta-catenin gene (CTNNB1). Genomics 32:413-424.
271. Nusse R. 1999. WNT targets: Repression and activation. Trends Genet 15:1-3.
272. Nürnberg P, Tinschert S. 2004. ANKH and craniometaphyseal dysplasia. In: Epstein CJ, Erickson RP, Wynshaw-Boris A, editors. Inborn Errors of Development, New York: Oxford University Press, Chapter 104, pp. 1007-1013.
273. Nürnberg P, Thiele H, Chandler D, Hohne W, Cunningham ML, Ritter H, Leschik G, Uhlmann K, Mischung C, Harrop K, Goldblatt J, Borochowitz ZU, Kotzot D, Westermann F, Mundlos S, Braun H-S, Laing N, Tinschert S. 2002. Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, result in craniometaphyseal dysplasia. Nat Genet 28:37-41.
274. Oldridge M, Lunt PW, Zackai EH, McDonald-McGinn DM, Muenke M, Moloney DM, Twigg SRF, Heath JK, Howard TD, Hoganson G, Gagnon DM, Jabs EW, Wilkie AOM. 1997. Genotype-phenotype correlations for nucleotide substitutions in the IgII-IgIII linker of FGFR2. Hum Mol Genet 6:137-143.
275. Oliveri MB, Mautalen CA, Rodriguez Fuchs CA, Romanelli MC. 1991. Vertebral compression fractures at the onset of acute lymphoblastic leukemia in a child. Henry Ford Hosp Med J 39:45-48.
276. OMIM. 2005. (Online Mendelian Inheritance in Man, 2005).
277. Oostra RJ, van der Harten HJ, Rijnders WPHA, Scott RJ, Young MPA, Trump D. 2000. Blomstrand osteochondrodysplasia: Three novel cases and histological evidence for heterogeneity. Virchows Arch 436:28-35.
278. Ornitz DM, Itoh N. 2001. Protein family review: Fibroblast growth factors. Genome Biol 2:3005.1-3005.12.
279. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, Stamp GWH, Beddington RSP, Mundlos S, Olsen BR, Selby PB, Owen MJ. 1997. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89:765-771.
280. Paiement GD, Chevrier N, Lorrain J, Perrier L, Coughlin RR. 1993. Osteoporosis: A preventable consequence of menopause. J Soc Obstol Gynaecol Canada 15:985-993.
281. Parr BA, McMahon AP. 1995. Dorsalizing signal Wnt-7 required for normal polarity of D-V and A-P axes of mouse limb. Nature 374:350-353.
282. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, Michaeli J, Epstein J, Choi Y. 2001. Multiple myeloma disrupts the TRANCE osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. 2001. Proc Natl Acad Sci USA 98:11581-11586.
283. Pendleton A, Johnson MD, Hughes A, Gurley KA, Ho AM, Doherty M, Dixey J, Gillet P, Loeuille D, McGrath R, Reginato A, Shiang R, Wright G, Netter P, Williams C, Kingsley DM. 2002. Mutations in ANKH cause chondrocalcinosis. Am J Hum Genet 71:933-940.
284. Peters H, Balling R. 1999. Teeth: Where and how to make them. Trends Genet 15:59-65.
285. Phillips JC, Del Bono EA, Haines JL, Pralea AM, Cohen JS, Greff LJ, Wiggs JL. 1996. A second locus for Rieger syndrome maps to chromosome 13q14. Am J Hum Genet 59:013-019.
286. Piepkorn B, Kann P, Forst T, Andreas J, Pfutzner A, Beyer J. 1997. Bone mineral density and bone metabolism in diabetes mellitus. Hormone Metab Res 29:584-591.
287. Price JA, Bowden DW, Wright JT, Pettenati MJ, Hart TC. 1998. Identification of a mutation in DLX3 associated with trichodento-osseous (TDO) syndrome. Hum Mol Genet 7:563-569.
288. Prinos P, Kilpatrick MW, Tsipouras P. 1995. A novel 346E FGFR3 mutation in achondroplasia. Pediatr Res 37:pt 2:151A.
289. Prinster C, Carrera P, Delmaschio M, Weber G, Maghnie M, Vigone MC, Mora S, Tonini G, Rigon F, Beluffi G. 1998. Comparison of clinical, radiological and molecular findings in hypochondroplasia. Am J Med Genet 75:109-112.
290. Pritchard JJ, Scott JH, Girgis FG. 1956. The structure and development of cranial and facial sutures. J Anat 90:73-86.
291. Quack I, Vonderstrass B, Stock M, Aylsworth AS, Becker A, Brueton L, Lee PJ, Majewski F, Mulliken JB, Suri M, Zenker M, Mundlos S, Otto F. 1999. Mutation analysis of core binding factor Al in patients with cleidocranial dysplasia. Am J Hum Genet 65:1266-1278.
292. Ralston SH. 1999. The genetics of osteoporosis. Bone 25:85-86.
293. Ramaswami U, Rumsby G, Hindmarsh PC, Brook CG. 1998. Genotype and phenotype in hypochondroplasia. J Pediatr 133:99-102.
294. Raskind WH, Conrad EU, Chansky H, Matsushita M. 1995. Loss of heterozygosity in chondrosarcomas for markers linked to hereditary multiple exostoses loci on chromosomes 8 and 11. Am J Hum Genet 56:1132-1139.
295. Rauch F, Glorieux FH. 2004. Osteogenesis imperfecta. Lancet 363:1377-1385.
296. Rauch F, Glorieux FH. 2005. Osteogenesis imperfecta, current and future medical treatment. Am J Med Genet Part C (Semin. Med. Genet.) 139C:31-37.
297. Rauch A, Opitz JM, Walker D. 1998. Syndromal foramina parietalia permagna: "New" or FG syndrome? Comments on the paper by Chrzanowska et al. [1998]. Am J Med Genet 78:406-407.
298. Rauch F, Lauzier D, Croteau S. 2000. Temporal and spatial expression of bone morphogenetic protein-2. -4, and -7 during distraction osteogenesis in rabbits. Bone 27:453-459.
299. Rauch F, Travers R, Norman ME, Taylor A, Parfitt AM, Glorieux FH. 2002. The bone formation defect in idiopathic juvenile osteoporosis is surface-specific. Bone 31:85-89.
300. Reddi AH, Binderman I. 1997. Bone morphogenetic proteins in context: New concepts for stomatology and craniofacial biology. In: Cohen MM, Jr., Baum BJ, editors. Studies in Stomatology and Craniofacial Biology. Amsterdam: IOS Press, Chap. 9, pp. 117-126.
301. Reya T, Clevers H. 2005. Wnt signalling in stem cells and cancer. Nature 434:843-850.
302. Rickard SJ, Wilson LC. 2003. Analysis of GNAS1 and overlapping transcripts identifies the paternal origin of mutations in patients with sporadic Albright hereditary osteodystrophy and reveals a model system in which to observe the effects of splicing mutations on translated and untranslated messenger RNA. Am J Hum Genet 72:901-974.
303. Robertson SP, Twigg SRF, Sutherland-Smith AJ, Biancalana V, Gorlin RJ, Horn D, Kenwrick SJ, Kim CA, Morava E, Newbury-Ecob R, Orstavik KH, Quarrell OWJ, Schwartz CE, Shears DJ, Suri M, Kendrick-Jones J, OPD-spectrum Disorders Clinical Collaborative Group, Wilkie AOM. 2003. Localized mutations in the gene encoding the cytoskeletal protein filamin A cause diverse malformations in humans. Nature Genet 33:487-491.
304. Robey PG, Fedarko NS, Veter UK. 1997. The role of in vitro analysis in unraveling the cause and providing the potential cure of osteogenesis imperfecta. In: Cohen MM, Jr., Baum B, editors. Studies in Stomatology and Craniofacial Biology. Amsterdam: IOS Press, Chap. 14, pp. 229-244.
305. Robitaille J, MacDonald MLE, Kaykas A, Sheldahl LC, Zeisler J, Dube M-P, Zhang L-H, Singaraja RR, Guernsey DL, Zheng B, Siebert LF, Hoskin-Mott A, Trese MT, Pimstone SN, Shastry BS, Moon RT, Hayden MR, Goldberg YP, Samuels ME. 2002. Mutant frizzled-4 disrupts retinal angiogenesis in familial exudative vitreoretinopathy. Nat Genet 32:326-330.
306. Rodan GA, Harada S. 1997. The missing bone. Cell 89:077-680.
307. Rohmann E, Brunner HG, Kayserili H, Uyguner O, Nurnberg G, Lew ED, Dobbie A, Eswarakumar VP, Uzumcu A, Ulubil-Emeroglu M, Leroy JG, Li Y. 2006. Mutations in different components of FGF signaling in LADD syndrome. Nat Genet 38:414-417.
308. Roodman GD, Kurihara N, Ohsaki Y, Kukita A, Hosking D, Demulder A, Smith JF, Singer FR. 1992. Interleukin 6: A potential autocrine/paracrine factor in Paget's disease of bone. J Clin Invest 89:46-52.
309. Rosen V, Thies RS. 1992. The BMP proteins in bone formation and repair. Trends Genet 8:97-102.
310. Rousseau F, Saugier P, Le Merrer M, Munnich A, Delezoide A-L, Maroteaux P, Bonaventure J, Narcy F, Sanak M. 1995. Stop codon FGFR3 mutations in thanatophoric dwarfism type I. Nat Genet 10:11-12.
311. Rousseau F, Bonaventure J, Legeai-Mallet L, Schmidt H, Weissenbach H, Maroteaux P, Munnich A, Le Merrer F. 1996a. Clinical and genetic heterogeneity of hypochondroplasia. J Med Genet 33:749-752.
312. Rousseau F, El Ghouzzi V, Delezoide A-L, Legeai-Mallet L, Le Merrer M, Munnich A, Bonaventure J. 1996b. Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TDI). Hum Mol Genet 5:509-512.
313. Ryu J-H, Kim S-J, Kim S-H, Oh C-D, Hwang S-G, Chun C-H, Oh S-H, Seong J-K, Huh T-L, Chun J-S. 2002. Regulation of the chondrocyte phenotype by β-catenin. Development 129:5541-5550.
314. Sadler TW, Potts LF. 1997. Making sense with antisense: Determining the roles of Msx genes in mouse whole embryo culture. In: Cohen MM, Jr., Baum BJ, editors. Studies in Stomatology and Craniofacial Biology. Amsterdam: IOS Press, pp. 59-66.
315. Salazar-Ciudad I, Jernvall J. 2002. A gene network model accounting for development and evolution of mammalian teeth. Proc Natl Acad Sci USA 99:8116-8120.
316. Salo J, Lehenkari P, Mulari M, Metsikkö K, Väänänen HK. 1997. Removal of osteoclast bone resorption products by transcytosis. Science 276:270-273.
317. Sato M, Mori E, Komori T, Kawahata H, Sugimoto M, Terai K, Shimizu H, Yasui T, Ogihara H, Yasui N, Ochi T, Kitamura Y, Ito Y, Nomura S. 1998. Transcriptional regulation of osteopontin gene in vivo by Pebp2αA/Cbfa1 and Ets1 in the skeletal tissue. Oncogene 17:1517-1525.
318. Satokata I, Maas R. 1994. Msx1 deficient mice exhibit cleft palate and abnormalities of craniofacial and tooth development. Nat Genet 6:348-356.
319. Schipani E, Kruse K, Juppner H. 1995. A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. Science 208:98-100.
320. Schlienger RG, Kraenzlin ME, Meier CR. 2004. Use of beta blockers and risk of fractures. JAMA 292:1320-1333.
321. Schmale GA, Conrad EU, Raskind WH. 1994. The natural history of hereditary multiple exostoses. J Bone Joint Surg 76A:986-992.
322. Schwindinger WF, Francomano CA, Levine MA. 1992. Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G-protein of adenylyl cyclase in McCune-Albright syndrome. Proc Natl Acad Sci USA 89:5152-5156.
323. Seitz M, Hunstein W. 1985. Enhanced prostanoid release from monocytes of patients with rheumatoid arthritis and active systemic lupus erythematosus. Ann Rheum Dis 44:438-445.
324. Selvamurugan N, Pulumati MR, Tyson DR, Partridge NC. 2000. Parathyroid hormone regulation of the rat collagenase-3 promoter by protein kinase. A-dependent transactivation of core binding factor alpha1. J Biol Chem 275:5037-5042.
325. Semina EV, Reiter R, Leysens NJ, Alward WLM, Small KW, Datson NA, Siegel-Bartelt J, Bierke-Nelson D, Bitoun P, Zabel BU, Carey JC, Murray JC. 1996. Cloning and characterization of a novel bicoid-related homeobox transcription factor gene, RIEG, involved in Rieger syndrome. Nat Genet 14:392-399.
326. Shafritz AB, Shore EM, Gannon FH, Zasloff MA, Taub R, Muenke M, Kaplan FS. 1996. Overexpression of an osteogenic morphogen in fibrodysplasia ossificans progressiva. N Engl J Med 335:555-561.
327. Sheen VL, Dixon PH, Fox JW, Hong SE, Kinton L, Sisodiya SM, Duncan JS, Dubeau F, Scheffer IE, Schachter SC, Wilner A, Henchy R. 2001. Mutations in the X-linked filamin 1 gene cause periventricular nodular heterotopia in males as well as in females. Hum Molec Genet 10:1775-1783.
328. Sheen VL, Feng Y, Graham D, Takafuta T, Shapiro SS, Walsh CA. 2002. Filamin A and filamin B are co-expressed within neurons during periods of neuronal migration and can physically interact. Hum Molec Genet 11:2845-2854.
329. Sheen VL, Jansen A, Chen MH, Parrini E, Morgan T, Ravenscroft R, Ganesh V, Underwood T, Wiley J, Leventer R, Vaid RR, Ruiz DE. 2005. Filamin A mutations cause periventricular heterotopia with Ehlers-Danlos syndrome. Neurology 64:254-262.
330. S. J Pediatr 123:509-518.
331. S alpha mutation is present in fibrous dysplasia of bone in the McCune-Albright syndrome. J Clin Endocrinol Metab 79:750-755.
332. Shenker A, Chanson P, Weinstein LS, Chi P, Spiegel AM, Lomri A, Marie PJ. 1995. Osteoblastic cells derived from isolated lesions of fibrous dysplasia contain activating somatic mutations of the G(s)-alpha gene. Hum Mol Genet 4:1675-1676.
333. Shiang R, Thompson LM, Zhu Y-Z, Church DM, Fielder TJ, Bocian M, Winokur ST, Wasmuth JJ. 1994. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 78:335-342.
334. Shiihara T, Kato M, Kimura T, Hayasaka K, Yamamori S, Ogata T. 2004. Research letter. Craniosynostosis with extra copy of MSX2 in a patient with partial 5q-trisomy. Am J Med Genet Part A 128A:214-216.
335. Shimada T, Mizutani S, Moto T, Yoneya T, Hino R, Takeda S, Takeuchi Y,
336. Shore EM, Ahn J, Jan de Beur S, Li M, Xu M, Gardiner RJM, Zasloff MA, Whyte MP, Levine MA, Kaplan FS. 2002. Paternally inherited inactivating mutations of the GNAS1 gene in progressive osseous heteroplasia. New Engl J Med 346:99-106.
337. Shore EM, Xu M, Feldman GJ, Fenstermacher DA, The FOP International Research Consortium, Brown MA, Kaplan FS. 2006. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 38:525-527.
338. Sillence DO, Senn A, Danks DM. 1979. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 10:101-110.
339. Sitsen AE. 1933. Zur Entwicklung der Nähte des Schädeldaches. Z Ges Anat Z Anat Entw-Gesch 101:121-152.
340. Sobacchi C, Frattini A, Orchard P, Porras O, Tezcan I, Andolina M, Babul-Hirji R, Baric I, Canham N, Chitayat D, Dupuis-Girod S, Ellis I, Etzioni A, Fasth A, Fisher A, Gerritsen B, Gulino V, Horwitz E, Klamroth V, Lanino E, Mirolo M, Musio A, Matthijs G, Nonomaya S, Notarangelo LD, Ochs HD, Furga AS, Valiaho J, van Hove JLK, Vihinen M, Vujic D, Vezzoni P, Villa A. 2001. The mutational spectrum of human malignant autosomal recessive osteopetrosis. Hum Mol Genet 10:1707-1773.
341. Sock E, Pagon RA, Keymolen K, Lissens W, Wegner M, Scherer G. 2003. Loss of DNA-dependent dimerization of the transcription factor SOX9as a cause for campomelic dysplasia. Hum Mol Genet 12:1439-1447.
342. Spiegel AM. 1997. The molecular basis of disorders caused by defects in G proteins. Horm Res 47:89-96.
343. Stefanova M, Meinecke P, Gal A, Bolz H. 2005. A novel 9 bp deletion in the filamin A gene causes an otopalatodigital-spectrum disorder with a variable intermediate phenotype. Am J Med Genet Part A 132A:386-390.
344. Stellon AJ, Davies A, Compston J, Williams R. 1985. Bone loss in autoimmune chronic active hepatitis on maintenance corticosteroid therapy. Gastroenterology 89:1078-1083.
345. Stockton DW, Das P, Goldenberg M, D'Souza RN, Patel PI. 2000. Mutation of PAX9 is associated with oligodontia. Nat Genet 24:18-19.
346. Stoilov I, Kilpatrick MW, Tsipouras P, Costa T. 1995. Possible genetic heterogeneity in hypochondroplasia. J Med Genet 32:492-493.
347. Stossel TP, Condeelis J, Cooley L, Hartwig JH, Naegel A, Schleicher M, Shapiro SS. 2001. Filamins as integrators of cell mechanics and signaling. Nat Rev Mol Cell Biol 2:138-145.
348. Strewler GJ. 2001. FGF23, hypophosphatemia, and rickets: Has phosphorylation been found? Proc Natl Acad Sci USA 98:5945-5946.
349. Superti-Furga A, Eich G, Bucher HU, Wisser J, Giedion A, Gitzelmann R, Steinmann B. 1995. A glycine 375-to-cysteine substitution in the transmembrane domain of the fibroblast growth factor receptor-3 in a newborn with achondroplasia. Eur J Pediatr 154:215.
350. Symons AL, Stritzel F, Stamatiou J. 1993. Anomalies associated with hypodontia of the permanent lateral incisor and second premolar. J Clin Pediatr Dent 17:109-111.
351. Szabo JK, Wilkin DJ, Cameron R, Henderson S, Bellus G, Kaitila I, Loughlin J, Munnich A, Sykes B, Bonaventure J, Francomano CA. 1997. The achondroplasia mutation occurs exclusively on the paternally derived fibroblast growth factor receptor 3 (FGFR3) allele. Am J Hum Genet 60(Suppl):Abstract No. 2040.
352. Taipale J, Beachy PA. 2001. The Hedgehog and Wnt signaling pathways in cancer. Nature 411:349-354.
353. Takayanagi H, Ogasawara K, Hida S, Chlba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, Nakamura K, Taniguchi T. 2002. T-cell-mediated regulation of osteoclastogenesis by signaling cross-talk between RANKL and IFN-γ. Nature 408:600-605.
354. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty G. 2002. Leptin regulates bone formation via the sympathetic nervous system. Cell 111:305-317.
355. Takeda S, Elefteriou F, Karsenty G. 2003. Common endocrine control of body weight, reproduction, and bone mass. Annu Rev Nutrit 23:403-411.
356. Tavormina PL, Rimoin DL, Cohn DH, Zhu Y-Z, Shiang R, Wasmuth JJ. 1995a. Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I. Hum Mol Genet 4:2175-2177.
357. Tavormina PL, Shiang R, Thompson LM, Zhu Y-Z, Wilkin DI, Lachnian RS, Wilcox WR, Rimoin DL, Cohn DH, Wasmuth JJ. 1995b. Thanatophoric dysplaia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat Genet 9:321-328.
358. Tavormina PL, Bellus GA, Webster MK, Bamshad MJ, Fraley AE, McIntosh I, Szabo J, Jiang W, Jabs EW, Wilcox WR. 1999. A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene. Am J Hum Genet 64:722-731.
359. Teitelbaum SL. 2000. Bone resorption by osteoclasts. Science 289:1504-1508.
360. The Canadian Consensus Conference on Menopause and Osteoporosis. 1998. Canadian consensus conference. J Soc Obstet Gynaecol Canada 20:1243-1272.
361. Theill LE, Boyle WJ, Penninger JM. 2002. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 20:795-823.
362. Thesleff I. 1998. The genetic basis of normal and abnormal craniofacial development. Acta Odontol Scand 56:321-325.
363. Thesleff I. 2003. Epithelial-mesenchymal signaling regulating tooth morphogenesis. J Cell Sci 116:1647-1648.
364. Thesleff I, Pirinen S. 2003. Genetics of dental defects. Encyclopedia of Human Genome. Genes & Diseases. New York: John Wiley and Sons Ltd.
365. Thesleff I, Mikkola M. 2002. The role of growth factors in tooth development. Int Rev Cytol 217:93-135.
366. Thesleff I, Åberg T. 1999. Molecular regulation of tooth development. Bone 25:123-125.
367. Thirunavukkarasu K, Mahajan M, McLarren KW, Stifani S, Karsenty G. 1998. Two domains unique to osteoblast-specific transcription factor Osf2/Cbfa1 contribute to its transactivation function and its inability to heterodimerize with Cbfbeta. Mol Cell Biol 18:4197-4208.
368. Thirunavukkarasu K, Halladay DL, Miles RR, Yang X, Galvin RJ, Chandrasekahar S, Martin TJ, Onyia JE. 2000. The osteoblast-specific transcription factor Cbfa1 regulates the expression of osteoprotegerin (OPG), a potent inhibitor of osteoclast differentiation and function. J Biol Chem 275:25163-25172.
369. Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, Martin TJ, Gillespie MT. 1999. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140:4451-4458.
370. Thong M-K, Scherer G, Kozlowski K, Haan E, Morris L. 2000. Acampomelic campomelic dysplasia with SOX9 mutation. Am J Med Genet 93:421-425.
371. Tinkle BT, Wenstrup RJ. 2005. A genetic approach to fracture epidemiology in childhood. Am J Med Genet Part C (Semin. Med. Genet.) 139C:38-34.
372. Tintut Y, Parhami F, Li V, Kasenty G, Demer LL. 1999. Inhibition of osteoblast-specific transcription factor Cbfa1 by the cAMP pathway in osteoblastic cells. Ubiquitin/proteasome-dependent regulation. J Biol Chem 274:28875-28879.
373. Tjalma RA. 1966. Canine bone sarcoma: Estimation of relative risk as a function of body size. J Natl Cancer Inst 36:1137-1150.
374. Toydemir R, Longo N, Brassington A, Bayrak-Toydemir P, Krakowiak P, Jorde LB. 2003. A new syndrome caused by a novel loss-of-function mutation in FGFR3. Am J Hum Genet Suppl 73:171.
375. Trémollières FA, Pouilles JM, Ribot C. 1993. Vertebral postmenopausal bone loss is reduced in overweight women: A longitudinal study in 155 early postmenopausal women. J Clin Endocrinol Metab 77:683-686.
376. Twigg SRF, Kan R, Babbs C, Bochukova EG, Robertson SP, Wall SA, Morriss-Kay GM, Wilkie AOM. 2004. Mutations of ephrin-B1 (EFNB1), a marker of tissue boundary formation, cause craniofrontonasal syndrome. Proc Natl Acad Sci USA 101:8652-8675.
377. Twigg SR, Matsumoto K, Kidd AMJ, Goriely A, Taylor IB, Fisher RB, Hoogeboom JM, Mathijssen IMJ, Lourenço MT, Morton JEV, Sweeney E, Wilson LC, Brunner HG, Mulliken JB, Wall SA, Wilkie AOM. 2006. The origin of EFNB mutations in craniofrontonasal syndrome: Frequent somatic mosaicism and explanation of the paucity of carrier males. Am J Hum Genet 78: (in press).
378. Urist MR. 1997. Bone morphogenetic protein: The molecularization of skeletal system development. J Bone Miner Res 12:343-346.
379. van den Boogaard MJ, Dorland M, Beemer FA, van Amstel HK. 2000. MSX1 mutation is associated with orofacial clefting and tooth agenesis in humans. Nat Genet 24:342-343.
380. van der Flier A, Sonnenberg A. 2001. Structural and functional aspects of filamins. Biochim Biophys Acta 1538:99-117.
381. Van Wesenbeeck L, Cleiren E, Gram J, Beals RK, Bénichou O, Scopelliti D, Key L, Renton T, Bartels C, Gong Y, Warman ML, de Vernejoul M-C, Bollerslev J, Van Hul W. 2003. Six novel missense mutations in the LDL receptor-related protein 5(LRP5) gene in different conditions with an increased bone density. Am J Hum Genet 72:763-771.
382. Vastardis H, Karimbux N, Guthua SW, Seidman JG, Seidman CE. 1996. A human MSX1 homeodomain missense mutation causes selective tooth agenesis. Nat Genet 13:417-421.
383. Vega RB, Matsuda K, Oh J, Barbosa AC, Yang X, Meadows E, McAnally J, Pomajzl C, Shelton JM, Richardson JA, Karsenty G, Olson EN. 2004. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 119:555-566.
384. Verloes A, Lesenfants S, Barr M, Grange DK, Journel H, Lombet J, Mortier G, Roeder E. 2000. Fronto-otopalatodigital osteodysplasia: Clinical evidence for a single entity encompassing Melnick-Needles syndrome, otopalatodigital syndrome types 1 and 2, and frontometaphyseal dysplasia. Am J Med Genet 90:407-422.
385. Vinkka H. 1982. Secondary cartilages in the facial skeleton of the rat. Proc Finnish Dent Soc 78(Suppl VII):5-137.
386. Vinkka-Puhakka T, Thesleff I. 1993. Initiation of secondary cartilage in the mandible of the Syrian hamster in the absence of muscle function. Arch Oral Biol 38:49-59.
387. Vortkamp A, Lee K, Lanske B, Segre GV, Kronenberg HM, Tabin CJ. 1996. Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein. Science 273:613-622.
388. Waggoner B, Kovach MJ, Winkelman M, Cai D, Khardori R, Gelber D, Kimonis VE. 2002. Heterogeneity in familial dominant Paget disease of bone and muscular dystrophy. Am J Med Genet 108:187-191.
389. Wakefield LM, Smith DM, Flanders KC, Sporn MD. 1988. Latent transforming growth factor-beta from human platelets: A high molecular weight complex containing precursor sequences. J Biol Chem 263:7646-7654.
390. Wallace SE, Lachman RS, Mekikian PB, Bui KK, Wilcox WR. 2004. Marked phenotypic variability in progressive diaphyseal dysplasia (Camurati-Engelmann disease): Report of a four-generation pedigree, identification of a mutation in TGFβ1, and review. Am J Med Genet Part A 129A:235-247.
391. Wang Y, Sassoon D. 1995. Ectoderm-mesenchyme and mesenchyme-mesenchyme interactions regulate Msx-1 expression and cellular differentiation in the murine limb bud. Dev Biol 168:374-382.
392. Warman ML, Mulliken JB, Hayward PG, Müller U. 1993. Newly recognized autosomal dominant disorder with craniosynostosis. Am J Med Genet 46:444-449.
393. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegal AM. 1991. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 325:1688-1695.
394. Wenstrup RJ. 1997. From genes to tissue in osteogenesis imperfecta: A long and winding road. In: Cohen MM, Jr., Baum BJ, editors. Studies in Stomatology and Craniofacial Biology. Amsterdam: IOS Press, Chap. 12, pp. 191-207.
395. Wenstrup RJ, Willing MC, Starman BJ, Byers PH. 1990. Distinct biochemical phenotypes predict clinical severity in nonlethal variants of osteogenesis imperfecta. Am J Hum Genet 46:975-982.
396. White KE, Jonsson KB, Carn G, Hampson G, Spector TD, Mannstadt M, Lorenz-Depiereux B, Miyauchi A, Yang IM, Ljunggren O. 2001. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocr Metab 86:497-500.
397. White KE, Cabral JM, Davis SI, Fishburn T, Evans WE, Ichikawa S, Fields J, Yu X, Shaw NJ, McLellan NJ, McKeown C, FitzPatrick D, Yu K, Ornitz DM, Econs MJ. 2005. Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. Am J Hum Genet 76:361-367.
398. Whyte MP, Reinus WH, Mumm S. 2004. High-bone-mass disease and LRP5. New Engl J Med 350:2096-2099.
399. Wilcox WR, Tavormina PL, Krakow D, Kitoh H, Lachman RS, Wasmuth JJ, Thompson LM, Rimoin DL. 1998. Molecular, radiologic, and histopathologic correlations in thanatophoric dysplasia. Am J Med Genet 78:274-281.
400. Wilkie AOM, Wall SA. 1996. Craniosynostosis: Novel insights into pathogenesis and treatment. Curr Opin Neurol 9:146-152.
401. Wilkie AOM, Slaney SF, Oldridge M, Poole MD, Ashworth GJ, Hockley AD, Hayward RD, David DJ, Pulleyn LJ, Rutland P, Malcolm S, Winter RM, Reardon W. 1995. Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. Nat Genet 9:165-172.
402. th Annual Meeting, San Francisco, California, October 19-23, Abstract No. 249.
403. Wilkie AOM. 2005. Bad bones, absent smell, selfish testes: The pleiotropic consequences of human FGF receptor mutations. Cytokine Growth Factor Rev 16:187-203.
404. Wilkie AOM, Bochukova EG, Hansen RMS, Taylor IB, Rannan-Eliya SV, Byren JC, Wall SA, Ramos L, Venâncio M, Hurst JA, O'Rourke AWO, Willismd LJ, Seller A, Lester T. 2006. Clinical dividends from the molecular genetic diagnosis of craniosynostosis. Am J Med Genet (in press).
405. Wilkin DJ, Szabo JK, Cameron R, Henderson S, Bellus GA, Mack ML, Kaitila I, Loughlin J, Munnich A, Sykes B. 1998. Mutations in fibroblast growth-factor receptor 3 in sporadic cases of achondroplasia occur exclusively on the paternally derived chromosome. Am J Hum Genet 63:711-716.
406. Williams JP, Blair HC, McDonald JM, McKenna MA, Jordan SE, Williford J, Hardy RW. 1997. Regulation of osteoclastic bone resorption by glucose. Biochem Biophys Res Commun 235:646-651.
407. Williams CJ, Zhang Y, Timms A, Bonavita G, Caeiro F, Broxholme J, Cuthbertson J, Jones Y, Marchegiani R, Reginato A, Russell RGG, Wordsworth BP, Carr AJ, Brown MA. 2002. Autosomal dominant familial calcium pyrophosphate dihydrate deposition disease is caused by mutation in the transmembrane protein ANKH. Am J Hum Genet 71:985-991.
408. Williams CJ, Pendleton A, Bonavita G, Reginato AJ, Hughes AE, Peariso S, Doherty M, McCarty DJ, Ryan LM. 2003. Mutations in the amino terminus of ANKH in two US families with calcium pyrophosphate dihydrate crystal deposition disease. Arthritis Rheum 48:2627-2631.
409. Williamson EA, Ince PG, Harrison D, Kendall-Taylor P, Harris PE. 1995. G-protein mutations in human pituitary adrenocorticotrophic hormone-secreting adenomas. Eur J Clin Invest 25:128-131.
410. Williams LJ, Lester T, Beaumont HJ, Crocker M, Noakes C, Stefanidou A, Sarri C, Bazopoulou-Kyrkanidou E, Seller A, Petersen MB, Wilkie AOM. 2005. A novel case of craniosynostosis caused by a 6p21 duplication that includes the entire RUNX2 gene. J Med Genet 42 Suppl 1:S106.
411. Winograd J, Reilly MP, Roe R, Lutz R, Laughner E, Xu X, Hu L, Asakura T, Vander Kolk C, Strandberg JD, Semenza GL. 1997. Perinatal lethality and multiple craniofadal malformations in MSX2 transgenic mice. Hum Mol Genet 6:369-379.
412. Winterpacht A, Hubert K, Stelzer C, Schweikardt T, Decker H, Spranger J, Zabel B. 2000. A novel mutation mFGFR-3 disrupts a putative N-glycosylation site and results in hypochondroplasia. Physiol Genomics 2:9-12.
413. Woods A, Wang G, Beier F. 2005. RhoA/ROCK signaling regulates Sox9 expression and actin organization during chondrogenesis. J Biol Chem 280:11626-11634.
414. Wozney JM, Rosen V, Celeste AJ, Mitsock CLM, Whitters MJ, Kriz RW, Hewick RM, Wang EA. 1998. Molecular clones and activities. Science 242:1528-1534.
415. Wysolmerski JJ, Cormier S, Philbrick WM, Dann P, Zhang JP, Roume J, Delezoide A-L, Silve C. 2001. Absence of functional type 1 parathyroid hormone (PTH)/PTH-related protein receptors in humans is associated with abnormal breast development and tooth impaction. Clin Endocrinol Metab 86:1788-1794.
416. Xiao G, Jiang D, Gopalakrishnan R, Franceschi RT. 2002. Fibroblast growth factor 2 induction of the osteocalcin gene requires MAPK activity and phosphorylation of the osteoblast transcription factor. Cbfa1/Runx2. J Biol Chem 277:36181-36187.
417. Xu M, Shore EM. 1998. Mutational screening of the bone morphogenetic protein 4 gene in a family with fibrodysplasia ossificans progressiva. Clin Orthop 346:53-58.
418. Xu MQ, Feldman G, Le Merrer M, Shugart YY, Glaser DL, Utizberea JA, Fardeau M, Connor JM, Triffitt J, Smith R, Shore EM, Kaplan FS. 2000. Linkage exclusion and mutational analysis of the noggin gene in patients with fibrodysplasia ossificans progressiva (FOP). Clin Genet 58:291-298.
419. Yabut SM Jr, Kenan S, Sissons HA. 1988. Malignant transformation of fibrous dysplasia; A case report and review of the literature. Clin Orthop 228:281-288.
420. Yamaguchi TP, Bradley A, McMahon AP, Jones S. 1999. A Wnt5a pathway underlies outgrowth of multiple structures in the vertebrate embryo. Development 126:1211-1223.
421. Yamashiro T, Åberg T, Levanon D, Groner Y, Thesleff I. 2002. Expression of Runx1, -2 and -3 during tooth, palate and craniofacial bone development. Gene Expression Patterns 2:109-112.
422. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. 1998. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602.
423. Yeh GL, Mathur S, Wivel A, Li M, Gannon FH, Ulied A, Audi L, Olmsted EA, Kaplan FS, Shore EM. 2000. GNAS1 mutation and Cbfa1 misexpression in a child with severe congenital platelike osteoma cutis. J Bone Miner Res 15:2063-2073.
424. Yin W, Smiley E, Germiller J, Mechan RP, Florer JB, Wenstrup RJ, Bonadio J. 1995. Isolation of a novel latent transforming growth factor-β binding protein gene (LTBP 2). J Biol Chem 270:10147-10160.
425. Yoshida CA, Furuichi T, Fujita T, Fukayama R, Kanatani N, Kobayashi S, Satake M, Takada K, Komori T. 2002. Core-binding factor beta interacts with Runx2 and is required for skeletal development. Nat Genet 32:633-638.
426. Young ID, Zuccollo JM, Broderick NJ. 1993. A lethal skeletal dysplasia with generalized sclerosis and advanced skeletal maturation: Blomstrand chondrodysplasia? J Med Genet 30:155-157.
427. Zeng L, Kempf H, Murtaugh LC, Sato ME, Lassar AB. 2002. Shh establishes an Nkx3.2/Sox9 autoregulatory loop that is maintained by BMP signals to induce somitic chondrogenesis. Genes Dev 16:1990-2005.
428. Zenker M, Rauch A, Winterpacht A, Tagariello A, Kraus C, Rupprecht T, Sticht H, Reis A. 2004. A dual phenotype of periventricular nodular heterotopia and frontometaphyseal dysplasia in one patient caused by a single FLNA mutation leading to two functionally different aberrant transcripts. Am J Hum Genet 74:731-737.
429. Zhang H, Apfelroth SD, Hu W, Davis EC, Sanguineti C, Bonadio J, Mecham RP, Ramirez F. 1994. Structure and expression of flbrillin-2, a novel microfibrillar component preferentially located in elastic matrices. J Cell Biol 124:855-863.
430. Zhang P, Jobert A-S, Couvineau A, Silve C. 1998. A homozygous inactivating mutation in the parathyroid hormone/ parathyroid hormone-related peptide receptor causing Blomstrand chondrodysplasia. J Clin Endocr Metab 83:3365-3368.
431. Zhang Y, Yasui N, Huang G, Fujii M, Hanai J, Noganii H, Ochi T, Miyazono K, Ito Y. 2000. A RUNX2/PEBP2αA/CBFA1 mutation displaying impaired transactivation and Smad interaction in cleidocranial dysplasia. Proc Natl Acad Sci USA 97:10549-10554.